SEARCH:   Advanced

Blood, 15 July 2005, Vol. 106, No. 2, pp. 650-657. Prepublished online as a Blood First Edition Paper on March 31, 2005; DOI 10.1182/blood-2004-08-3344. This Article Full Text (PDF) All Versions of this Article: 2004-08-3344v1 106/2/650    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Oppezzo, P. Articles by Davi, F. Search for Related Content PubMed PubMed Citation Articles by Oppezzo, P. Articles by Davi, F. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted August 30, 2004 Accepted February 25, 2005 The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia Pablo Oppezzo, Yuri Vasconcelos, Catherine Settegrana, Dominique Jeannel, Francoise Vuillier, Magali Legarff-Tavernier, Eliza Yuriko Kimura, Stephane Bechet, Gerard Dumas, Martine Brissard, Helene Merle-Beral, Mihoko Yamamoto, Guillaume Dighiero, and Frederic Davi* Unite d'Immuno-Hematologie et Immunopathologie, Institut Pasteur, Paris, France Disciplina de Hematologia e Hemoterapia, Universade Federal de Sao Paulo, Sao Paulo, Brazil Service d'Hematologie Biologique, Hopital Pitie-Salpetriere, Paris, France Departement des Ecosystemes et Epidemiologie des Maladies Infectieuses, Institut Pasteur, Paris, France Service Immunologie, Hopital Pitie-Salpetriere, Paris, France Centre de Recherche Vaccinale et Biomedicale, Institut Pasteur, Paris, France * Corresponding author; email: fred.davi{at}psl.ap-hop-paris.fr. While ZAP-70 is over-expressed in CLL patients displaying unmutated IgVH genes and poor prognosis, a previous microarray study from our group identified overexpression of LPL and ADAM29 genes among unmutated and mutated CLLs respectively. To assess the prognostic value of these genes, we quantified their expression by RQ-PCR in a cohort of 127 CLL patients, and correlated this with clinical outcome, IgVH mutational status and ZAP-70 protein expression. IgVH mutational status, ZAP-70 and the LPL and ADAM29 mRNA ratios (L/A ratio) were predictive of event-free survival for the whole cohort and for stage A patients. In stage B and C patients, the L/A ratio was an independent prognostic factor while ZAP-70 did not predict survival. Simultaneous usage of the L/A ratio and ZAP-70 expression allowed an almost perfect (99%) assessment of the IgVH status in the 80% of patients with concordant results (L/A+, ZAP-70+ or L/A-, ZAP-70-). LPL and ADAM29 gene expression could also be determined by a simple competitive multiplex RT-PCR assay. Overall, quantification of LPL and ADAM29 gene expression is a strong prognostic indicator in CLL, providing better prognotic assessment than ZAP-70 in advanced stages of the disease. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. BOELENS, S. LUST, B. VANHOECKE, and F. OFFNER Chronic Lymphocytic Leukaemia Anticancer Res, February 1, 2009; 29(2): 605 - 615. [Abstract] [Full Text] [PDF] E. J. Lewintre, C. R. Martin, C. G. Ballesteros, D. Montaner, R. F. Rivera, J. R. Mayans, and J. Garcia-Conde Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia Haematologica, February 1, 2009; 94(2): 280 - 284. [Abstract] [Full Text] [PDF] T. J. Kipps Chronic Lymphocytic Leukemia: Advances in Assessing Prognosis and Therapy ASCO Educational Book, January 1, 2009; 2009(1): 385 - 393. [Abstract] [Full Text] [PDF] A. Mankai, A. Bordron, Y. Renaudineau, C. Martins-Carvalho, S. Takahashi, I. Ghedira, C. Berthou, and P. Youinou Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells Cancer Res., September 15, 2008; 68(18): 7512 - 7519. [Abstract] [Full Text] [PDF] R. Proto-Siqueira, R. A. Panepucci, F. P. Careta, A. Lee, A. Clear, K. Morris, C. Owen, E. G. Rizzatti, W. A. Silva Jr, R. P. Falcao, et al. SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL Blood, July 15, 2008; 112(2): 394 - 397. [Abstract] [Full Text] [PDF] A. W. Hauswirth and U. Jager Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia Haematologica, January 1, 2008; 93(1): 14 - 19. [Full Text] [PDF] J. G. Gribben Molecular Profiling in CLL Hematology, January 1, 2008; 2008(1): 444 - 449. [Abstract] [Full Text] [PDF] S. Deaglio, T. Vaisitti, S. Aydin, L. Bergui, G. D'Arena, L. Bonello, P. Omede, M. Scatolini, O. Jaksic, G. Chiorino, et al. CD38 and ZAP-70 are functionally linked and mark CLL cells with high migratory potential Blood, December 1, 2007; 110(12): 4012 - 4021. [Abstract] [Full Text] [PDF] L. V. Abruzzo, L. L. Barron, K. Anderson, R. J. Newman, W. G. Wierda, S. O'Brien, A. Ferrajoli, M. Luthra, S. Talwalkar, R. Luthra, et al. Identification and Validation of Biomarkers of IgVH Mutation Status in Chronic Lymphocytic Leukemia Using Microfluidics Quantitative Real-Time Polymerase Chain Reaction Technology J. Mol. Diagn., September 1, 2007; 9(4): 546 - 555. [Abstract] [Full Text] [PDF] F. Van Bockstaele, V. Pede, A. Janssens, F. Callewaert, F. Offner, B. Verhasselt, and J. Philippe Lipoprotein Lipase mRNA Expression in Whole Blood Is a Prognostic Marker in B Cell Chronic Lymphocytic Leukemia Clin. Chem., February 1, 2007; 53(2): 204 - 212. [Abstract] [Full Text] [PDF] A. M. Buhl, J. Jurlander, F. S. Jorgensen, A. M. Ottesen, J. B. Cowland, L. M. Gjerdrum, B. V. Hansen, and H. Leffers Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia Blood, April 1, 2006; 107(7): 2904 - 2911. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020